Successful conclusion of 2011 business year | All motions approved | Dividend of CHF 1.10 per share
Dietlikon, 4 April 2012 – The Annual General Meeting of Implenia AG approved all the motions of the Board of Directors. Against the background of the very good results for 2011 and the positive outlook for the current year, the shareholders approved an increased dividend in the form of a distribution of capital reserves amounting to CHF 1.10 per share (previous year: CHF 0.90 per share in the form of a reduction in par value).
The retiring members of the Board of Directors Toni Wicki and Philippe Zoelly were again thanked for all their work on behalf of Implenia. The Group is currently seeking suitable personalities to occupy the vacant seats on the Board, including candidates from French-speaking Switzerland.
The General Meeting brought the 2011 business year to a successful conclusion. On the strength of full order books, Implenia can look forward to the future with optimism. On 31 March 2012, the Group’s order book was at the outstandingly high level of CHF 3065 million.
Medie Contact Implenia:
Head of Communications
Phone: +41 44 805 45 23
Implenia is Switzerland's leading construction and construction services company. Formed in 2006 from the merger between Zschokke and Batigroup, Implenia can look back on more than 140 years of history in the construction industry. The company brings the expertise of its highly skilled Real Estate, Infrastructure Construction and Industrial Construction divisions under the single roof of a nationally and internationally active company. With its integrated business model and specialists operating in all its divisions, Implenia can manage a building project through its entire lifecycle and deliver work that is economical, sustainable, integrated and customer-centric.
Implenia, with its headquarters in Dietlikon near Zurich, employs more than 6,000 people and posted turnover of more than CHF 2.5 billion in 2011. The company is listed on the SIX Swiss Exchange (IMPN, CH0023868554). More information can be found at www.implenia.com.